Showing results (71-80 of 180) with videos related to
Sort By:
Pageof 18
British Journal of Haematology|April 21, 2015
Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trialSteve Schey, Sarah R Brown, Avie-Lee Tillotson, et al.Cancer Research|September 19, 2007
The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cellsYasser M El-Sherbiny, Josephine L Meade, Tim D Holmes, et al.Plos One|August 27, 2024
Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registryAdam Irving, Dennis Petrie, Anthony Harris, et al.Blood Cancer Journal|January 4, 2023
The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic reviewHira Mian, Arleigh McCurdy, Smith Giri, et al.Leukemia & Lymphoma|September 22, 2016
Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meetingLaurent Garderet, Gordon Cook, Holger W Auner, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2010
T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphomaKirsty J Thomson, Emma C Morris, Don Milligan, et al.Trials|March 9, 2018
The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trialAlina Striha, A John Ashcroft, Anna Hockaday, et al.British Journal of Haematology|March 10, 2023
Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trialSian E Faustini, Andrew Hall, Sarah Brown, et al.British Journal of Haematology|March 9, 2011
Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host diseaseBronwen E Shaw, Jane F Apperley, Nigel H Russell, et al.Blood|August 12, 2004
Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphomaEmma Morris, Kirsty Thomson, Charles Craddock, et al.Pageof 18